Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16.10. | BIODLINK-B (01875): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO CHANGE OF DIRECTORS, CHIEF EXECUTIVE OFFICER, AUTHORISED REPRESENTATIVE AND COMPOSITION OF ... | 1 | HKEx | ||
BIODLINK INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
13.10. | BIODLINK-B (01875): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
13.10. | BIODLINK-B (01875): CHANGE OF DIRECTORS, CHIEF EXECUTIVE OFFICER, AUTHORISED REPRESENTATIVE AND COMPOSITION OF BOARD COMMITTEE | 1 | HKEx | ||
26.09. | BIODLINK-B (01875): INTERIM REPORT 2025 | - | HKEx | ||
14.08. | BIODLINK-B (01875): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
14.08. | BIODLINK-B (01875): LETTER TO REGISTERED SHAREHOLDERS - NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
14.08. | BioDlink's bevacizumab receives marketing approval in Colombia, Pakistan | 1 | Pharmaceutical Business Review | ||
12.08. | BIODLINK-B (01875): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 | - | HKEx | ||
31.07. | BIODLINK-B (01875): DATE OF BOARD MEETING | - | HKEx | ||
25.07. | TOT BIOPHARM-B (01875): AMENDED AND RESTATED ARTICLES OF ASSOCIATION | - | HKEx | ||
25.07. | TOT BIOPHARM-B (01875): CHANGE OF COMPANY ENGLISH NAME, AMENDMENTS TO THE ARTICLES OF ASSOCIATION, CHANGE OF STOCK SHORT NAME, CHANGE OF COMPANY WEBSITE ... | - | HKEx | ||
30.06. | TOT BIOPHARM-B (01875): TERMS OF REFERENCE FOR THE NOMINATION COMMITTEE | - | HKEx | ||
20.06. | TOT BIOPHARM-B (01875): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 20 JUNE 2025 | - | HKEx | ||
06.06. | BioDlink Gains Argentina GMP Certification | 1 | Contract Pharma | ||
28.05. | TOT BIOPHARM-B (01875): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
28.05. | TOT BIOPHARM-B (01875): NOTIFICATION LETTER AND REQUEST FORM FOR REGISTERED SHAREHOLDERS | - | HKEx | ||
28.05. | TOT BIOPHARM-B (01875): FORM OF PROXY | - | HKEx | ||
28.05. | TOT BIOPHARM-B (01875): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
28.05. | TOT BIOPHARM-B (01875): PROPOSALS FOR GENERAL MANDATES TO ISSUE AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS, CHANGE OF COMPANY ENGLISH NAME ... | - | HKEx | ||
28.05. | TOT BIOPHARM-B (01875): PROPOSED CHANGE OF COMPANY ENGLISH NAME AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 2 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 42,270 | +0,49 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
VENTYX BIOSCIENCES | 7,235 | +87,44 % | Ventyx Biosciences: NBC feiert Daten-Knall und +928% in 6 Monaten | Der Party-Herbst reißt nicht ab: Nach dem Tenbagger Minerva explodieren im No Brainer Club die nächsten Kurs-Granaten. Eine davon ist die Aktie von Ventyx Biosciences. Die Ventyx-Aktie hatte der No... ► Artikel lesen | |
TANGO THERAPEUTICS | 8,010 | -7,51 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces $225 Million Financing | BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
EVOTEC | 6,866 | +2,08 % | Übernahme von Vidac Pharma und Evotec? 400 Mrd. USD bei Pfizer, Merck und Co im Feuer! | Alarm bei Big Pharma! Donald Trump scheint bei der Reduzierung von Medikamentenpreisen ernst zu machen. Gleichzeitig laufen Patente bei Blockbustern aus und ein 400 Mrd. USD Umsatzausfall droht. Pfizer... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,710 | -0,61 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
BIONTECH | 89,10 | -2,78 % | Wer im Kampf gegen Krebs auf jeden Fall verdient: NetraMark, Moderna, BioNTech | Zwei Biotech-Pioniere, Moderna und BioNTech, stehen nach ihrem COVID-19-Impfstoff-Erfolg erneut im Rampenlicht - diesmal in einem Wettrennen um innovative Krebstherapien. Beide Unternehmen setzen auf... ► Artikel lesen | |
HARMONY BIOSCIENCES | 29,555 | +12,59 % | Harmony Biosciences reports Q3 revenue of $239M, raises FY25 revenue guidance | ||
JANUX THERAPEUTICS | 24,520 | -6,87 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 48,250 | +2,97 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
89BIO | 14,800 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
COGENT BIOSCIENCES | 14,765 | -0,44 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib | Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 18,890 | -1,31 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 179,06 | -2,86 % | Praxis Precision Medicines prices $525M public offering | ||
JYONG BIOTECH | 61,00 | +0,59 % | Jyong Biotech Ltd.: Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS-8 for Prostate Cancer Prevention | New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company", "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
INHIBRX BIOSCIENCES | 31,350 | -0,48 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Second Quarter 2025 Financial Results | SAN DIEGO, Aug. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second... ► Artikel lesen |